EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety assessment of disulfiram: real-world adverse event analysis based on FAERS database

Jing Luo, Yaqi Zeng, Zhe Chen, Yaan Luo, Li Shi, Xuhui Zhou

Frontiers in Psychiatry · 19.11.2024 · 15

DOI: 10.3389/fpsyt.2024.1498204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 19.11.2024. Verfasst von Jing Luo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, The School of Clinical Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Disulfiram, an FDA-approved medication for AUD, has shown significant potential as a repurposed drug in therapeutic areas including oncology and infectious diseases. The purpose of study is to analyze adverse events (AEs) associated with disulfiram by examining the FAERS database, with a focus on understanding its safety profile in both traditional and emerging applications.

Methods

AE reports concerning disulfiram in the FAERS database from the fourth quarter of 2002 to the third quarter of 2023 were extracted. Various signal detection methods, including ROR, PRR, BCPNN, and MGPS, were used to detect and categorize adverse events.

Results

The study collected 52,159,321 AE reports, with 508 reports primarily suspecting disulfiram, identifying 104 Preferred Terms (PTs) across 25 System Organ Classes (SOCs). Major categories of AEs included off label use, psychiatric symptom, liver transplant, and polyneuropathy, with off label use being notably the most reported issue. Strong and new potential AEs were identified, including neurological and psychiatric issues like hypomania, delirium, and vocal cord paralysis; cardiac issues such as electrocardiogram st segment depression; and off label use-related issues like Jarisch-Herxheimer reaction.

Conclusion

Disulfiram poses risks of various adverse reactions while having promise as a “repurposed” agent. In clinical applications, practitioners should closely monitor occurrences of hepatobiliary disorders, psychiatric disorders, and nervous system disorders.

Schlagwörter

Stichwörter der Autor:innen

FAERSadverse eventdisulfiramreal-world data analysissignal mining

Autor:innen und Institutionen

  • Department of Psychiatry, The School of Clinical Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
  • Department of Psychiatry, The Second People's Hospital of Hunan Province (Brain Hospital of Hunan Province), Changsha, Hunan, China.
  • Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Zitieren

APA

Luo, J., Zeng, Y., Chen, Z., Luo, Y., Shi, L., & Zhou, X. (2024). Safety assessment of disulfiram: real-world adverse event analysis based on FAERS database. Frontiers in Psychiatry, 15. https://doi.org/10.3389/fpsyt.2024.1498204

Vancouver

Luo J, Zeng Y, Chen Z, Luo Y, Shi L, Zhou X. Safety assessment of disulfiram: real-world adverse event analysis based on FAERS database. Frontiers in Psychiatry. 2024;15. doi:10.3389/fpsyt.2024.1498204

BibTeX
@article{Luo2024,
  author = {Luo, Jing and Zeng, Yaqi and Chen, Zhe and Luo, Yaan and Shi, Li and Zhou, Xuhui},
  title = {Safety assessment of disulfiram: real-world adverse event analysis based on FAERS database},
  journal = {Frontiers in Psychiatry},
  year = {2024},
  volume = {15},
  doi = {10.3389/fpsyt.2024.1498204}
}
Kostenlos starten →